Niva Bupa Health Insurance Company (NIVABUPA) Investor update summary

Regulatory context and outlook

• IRDAI's consultation paper on distribution reforms is expected to be implemented by April 2027, with comments due by late October.

• Management views the proposed reforms as a net positive for both the industry and the company, especially in retail health.

• The reforms are anticipated to drive sustained volume growth, customer benefits, and improved economics.

Channel-wise impact and growth strategy

• Agency commissions are largely aligned with current levels, supporting continued growth and economics.

• Direct-to-consumer (DTC) remains highly attractive, with ongoing investment planned due to its superior economics and brand value.

• Bank distribution is expected to see growth, with incremental investments to offset lower commissions and maintain profitability.

• Digital broking, especially via Policybazaar, is expected to sustain strong growth, with business model adjustments as needed.

Financial and operational implications

• Expense of management (EoM) is projected to decline from 34% to 25% over three years, mainly due to commission moderation.

• Operating leverage from business growth is expected to further reduce EoM to 20% over five years without significant cost cuts.

• Combined ratio guidance remains at 98–99%, with potential acceleration toward targets due to reforms.

• Profitability is expected to improve in the short term, with long-term neutrality as benefits are passed to customers.